Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

12526

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions: TAK-411; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
Interventions: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Chemotherapy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 194
States / cities: Kingman, Arizona • Phoenix, Arizona • Beverly Hills, California + 151 more

Conditions: Narcolepsy Type 1, Narcolepsy Type 2
Interventions: cleminorexton, Placebo; Drug
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Brandon, Florida + 20 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel; Drug · Biological · Radiation
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: La Jolla, California • Farmington, Connecticut • New Haven, Connecticut + 14 more

Conditions: Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Apache Junction, Arizona + 61 more

Conditions: Leukemia, Myeloid, Acute
Interventions: Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 61
States / cities: Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Rina-S; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Fountain Valley, California • Irvine, California • San Diego, California + 17 more

Conditions: Major Depressive Disorder
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more

Conditions: Rett Syndrome
Interventions: fenfluramine hydrochloride, Placebo; Drug · Other
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 5 Years to 35 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 8
States / cities: Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 5 more

Conditions: Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage (ICH)
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 63
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 55 more

Clinical trials in Miami, Florida

Filter and sort this location

Live official records

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

Sleep to Predict Recovery In Unconscious Patients With Acute Brain Injury

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus